



## OPEN ACCESS

EDITED AND REVIEWED BY  
Iván Murrieta-Álvarez,  
Baylor College of Medicine, United States

\*CORRESPONDENCE  
Yahveth Cantero-Fortiz  
✉ ycantero@fundacioace.org

†These authors have contributed equally to this work

RECEIVED 11 October 2024  
ACCEPTED 16 October 2024  
PUBLISHED 29 October 2024

CITATION  
Cantero-Fortiz Y and Boada M (2024)  
Corrigendum: The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review. *Front. Neurol.* 15:1509655. doi: 10.3389/fneur.2024.1509655

COPYRIGHT  
© 2024 Cantero-Fortiz and Boada. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review

Yahveth Cantero-Fortiz 1,2\*† and Mercè Boada 1,2†

<sup>1</sup>Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain,  
<sup>2</sup>Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

## KEYWORDS

Alzheimer's disease, plasma exchange, albumin replacement, cognitive function, amyloid-beta, neurodegenerative disorders

## A Corrigendum on

[The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review](#)

by Cantero-Fortiz, Y., and Boada, M. (2024). *Front. Neurol.* 15:1443132. doi: 10.3389/fneur.2024.1443132

In the published article, there was an error regarding the significance of the results using “ $p < 0.05$ ” instead of “ $p > 0.05$ .” Despite the Clinical relevance, there was no statistical significance.

A correction has been made to the **Results** section, subsection *Neuropsychological and quality-of-life section assessments*, paragraph 26. The sentence originally stated:

“The study employed standardized tests such as the Mini-Mental State Examination (MMSE) and the AD Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) which showed statistically significant improvements ( $p < 0.05$ ) in the treatment group over the 21 weeks treatment period plus 6 months follow-up.”

The correct sentence should be:

“The study employed standardized tests such as the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) which demonstrated clinical improvements in the treatment group. However, these improvements did not reach statistical significance ( $p > 0.05$ ) over the 21-week treatment period plus 6 months of follow-up.”

Additionally, the term “AD disease” was used redundantly in several paragraphs.

A correction has been made throughout the article, [Paragraphs 11, 12, 14, 20, 21, 22, 26, and 35]. These sentences previously stated:

“AD disease”

The corrected sentences now state:

“AD”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.